ישראל -
עברית -
Ministry of Health
סטימופיל 300 מקג0.5 מל
tzamal bio-pharma ltd - filgrastim - תמיסה להזרקה\אינפוזיה - filgrastim 300 mcg / 0.5 ml - filgrastim
ישראל -
עברית -
Ministry of Health
סטימופיל 480 מקג0.5 מל
tzamal bio-pharma ltd - filgrastim - תמיסה להזרקה\אינפוזיה - filgrastim 480 mcg / 0.5 ml - filgrastim
ישראל -
עברית -
Ministry of Health
קריסויטה 10 מג
medison pharma ltd - burosumab - תמיסה להזרקה - burosumab 10 mg / 1 ml - burosumab
ישראל -
עברית -
Ministry of Health
קריסויטה 20 מג
medison pharma ltd - burosumab - תמיסה להזרקה - burosumab 20 mg / 1 ml - burosumab
ישראל -
עברית -
Ministry of Health
קריסויטה 30 מג
medison pharma ltd - burosumab - תמיסה להזרקה - burosumab 30 mg / 1 ml - burosumab
ישראל -
עברית -
Ministry of Health
פגיל
unipharm trading ltd, israel - pegfilgrastim - תמיסה להזרקה - pegfilgrastim 10 mg/ml - pegfilgrastim
ישראל -
עברית -
Ministry of Health
פגפילגרסטים קמהדע
kamada ltd, israel - pegfilgrastim - תמיסה להזרקה - pegfilgrastim 10 mg/ml - pegfilgrastim
ישראל -
עברית -
Ministry of Health
אמיודקור זריקות
sanofi israel ltd - amiodarone hydrochloride - תמיסה להזרקה - amiodarone hydrochloride 50 mg / 1 ml - amiodarone - amiodarone - corronary insufficiency, arrhythmias resistant to other treatments, wolf parkinson white syndrome.
ישראל -
עברית -
Ministry of Health
היקמטין 0.25 מג
novartis israel ltd - topotecan as hydrochloride - קפסולות ג'לטין קשיחות - topotecan as hydrochloride 0.25 mg - topotecan - topotecan - indicated for the treatment of patients with relapsed small cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate.
ישראל -
עברית -
Ministry of Health
אפיניטור 5 מג
novartis israel ltd - everolimus - טבליה - everolimus 5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*